Journal for ImmunoTherapy of Cancer

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
Kellsye P Fabian, Michelle R Padget, Renee N. Donahue, Kristen Solocinski, Yvette Robbins, Clint T. Allen, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James W Hodge

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000450; DOI: 10.1136/jitc-2019-000450
Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
Stijn JH Waaijer, Danique Giesen, Takahiro Ishiguro, Yuji Sano, Naofumi Sugaya, Carolina P Schröder, Elisabeth GE de Vries, Marjolijn N Lub-de Hooge

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000548; DOI: 10.1136/jitc-2020-000548
HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
Qiang-Hua Zhou, Kai-Wen Li, Xu Chen, Hai-Xia He, Sheng-Meng Peng, Shi-Rong Peng, Qiong Wang, Ze-An Li, Yi-Ran Tao, Wen-Li Cai, Ran-Yi Liu, Hai Huang

Journal for ImmunoTherapy of Cancer Jan 2020, 8 (1) e000157; DOI: 10.1136/jitc-2019-000157
Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes
Tonke K Raaijmakers, Renske J E van den Bijgaart, Martijn H den Brok, Melissa Wassink, Annemarie de Graaf, Jori A Wagenaars, Stefan Nierkens, Marleen Ansems, Gert Jan Scheffer, Gosse J Adema

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000649; DOI: 10.1136/jitc-2020-000649
Cell death induced by cytotoxic CD8⁺ T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens
Paula Jaime-Sanchez, Iratxe Uranga-Murillo, Nacho Aguilo, Sofia C Khouili, Maykel A Arias, David Sancho, Julian Pardo

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000528; DOI: 10.1136/jitc-2020-000528
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
Hanne Lind, Sofia R Gameiro, Caroline Jochems, Renee N. Donahue, Julius Strauss, James L Gulley, Claudia Palena, Jeffrey Schlom

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000433; DOI: 10.1136/jitc-2019-000433
Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy
William Murray-Brown, Tom D Wilsdon, Helen Weedon, Susanna Proudman, Shawgi Sukumaran, Sonja Klebe, Jennifer G Walker, Malcolm D Smith, Mihir D Wechalekar

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000281; DOI: 10.1136/jitc-2019-000281
Correction: The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000155corr1; DOI: 10.1136/jitc-2019-000155corr1
Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
Tanja Stüber, Razieh Monjezi, Lars Wallstabe, Johanna Kühnemundt, Sarah Louise Nietzer, Gudrun Dandekar, Achim Wöckel, Hermann Einsele, Jörg Wischhusen, Michael Hudecek

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000676; DOI: 10.1136/jitc-2020-000676
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
Wenjie Zhang, Yang Liu, Zhongyi Yan, Hui Yang, Wei Sun, Yongliang Yao, Yun Chen, Runqiu Jiang

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000285; DOI: 10.1136/jitc-2019-000285

Main menu

Journal for ImmunoTherapy of Cancer

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Journal for ImmunoTherapy of Cancer

Pages